Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syntara Limited (SNT.AX)
Frenchs Forest, NSW, AU
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.89% | +3.85% | -3.57% | -12.90% | -15.63% | -22.86% | -58.46% | -50.00% | -66.67% | -89.81% | -94.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0% Q4'23: -86.6% (vs Q4'21)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+69.4% ★ Q4'23: -34.9% (vs Q4'21)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%— Q4'23: -732.0% (vs Q4'21)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%— Q4'23: -742.7% (vs Q4'21)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1,191.7% Q4'23: -2,232.4% (vs Q4'21)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+124.1% Q4'23: +43.7% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.01× Q4'23: 0.00× (vs Q4'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 2 Rev. Ana. 1 EPS Ana. |
Jun 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
6.10M
est.
|
—
est: 2.23M (-100.0%)
|
2.60M
2.60M – 2.60M
+16.4% YoY
|
17.87M
17.87M – 17.87M
+587.2% YoY
|
5.13M
4.95M – 5.32M
-71.3% YoY
|
| EBITDA |
-2.35M
est.
|
-12.00M
est: -860.2K (-1,295.5%)
|
-1.00M
-1.00M – -1.00M
-16.4% YoY
|
-6.88M
-6.88M – -6.88M
-587.2% YoY
|
-1.98M
-2.05M – -1.91M
+71.3% YoY
|
| EBIT |
-2.87M
est.
|
-12.23M
est: -1.05M (-1,064.7%)
|
-1.22M
-1.22M – -1.22M
-16.4% YoY
|
-8.40M
-8.40M – -8.40M
-587.2% YoY
|
-2.41M
-2.50M – -2.33M
+71.3% YoY
|
| Net Income |
-30.86M
est.
|
-7.92M
est: -11.02M (+28.1%)
|
-8.08M
-8.08M – -8.08M
+26.7% YoY
|
7.35M
7.35M – 7.35M
+190.9% YoY
|
-9.55M
-9.55M – -9.55M
-230.0% YoY
|
| SGA |
13.14M
est.
|
9.00M
est: 4.81M (+87.0%)
|
5.60M
5.60M – 5.60M
+16.4% YoY
|
38.48M
38.48M – 38.48M
+587.2% YoY
|
11.06M
10.66M – 11.45M
-71.3% YoY
|
| EPS |
-0.02
est.
|
-0.01
est: -0.01 (+29.3%)
|
-0.01
-0.01 – -0.01
+26.7% YoY
|
0.01
0.01 – 0.01
+190.9% YoY
|
-0.01
-0.01 – -0.01
-230.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gary Jonathan Phillips | Chief Executive Officer, MD & Director | 697.2K | male |
| Wolfgang G. Jarolimek | Head of Drug Discovery | 507.4K | — |
| Timothy Luscombe | Chief Financial Officer & Company Secretary | 482.4K | male |
| Jana Baskar | Chief Medical Officer | 428.2K | — |
| Kristen Morgan | Head of Medical & Regulatory Affairs - Alliance Management | 343.1K | female |
| Cameron David Billingsley | General Counsel | — | male |
| Dieter Hamprecht | Head of Chemistry | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNT.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
